当前位置:
X-MOL 学术
›
Lancet Haematol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma
The Lancet Haematology ( IF 15.4 ) Pub Date : 2022-06-27 , DOI: 10.1016/s2352-3026(22)00169-7 Yun Kyoung Ryu 1 , Jennifer E Amengual 1
The Lancet Haematology ( IF 15.4 ) Pub Date : 2022-06-27 , DOI: 10.1016/s2352-3026(22)00169-7 Yun Kyoung Ryu 1 , Jennifer E Amengual 1
Affiliation
Abstract not available
中文翻译:
轻而易举!新型 EZH2 抑制剂 SHR2554 对复发或难治性淋巴瘤安全有效
摘要不可用
更新日期:2022-06-27
中文翻译:
轻而易举!新型 EZH2 抑制剂 SHR2554 对复发或难治性淋巴瘤安全有效
摘要不可用